Development of an Aerosol Dose Collection Apparatus for In Vitro Dissolution Measurements of Orally Inhaled Drug Products.
aerosol
bioequivalence
dissolution
inhaled corticosteroids
Journal
The AAPS journal
ISSN: 1550-7416
Titre abrégé: AAPS J
Pays: United States
ID NLM: 101223209
Informations de publication
Date de publication:
13 02 2020
13 02 2020
Historique:
received:
15
08
2019
accepted:
10
01
2020
entrez:
16
2
2020
pubmed:
16
2
2020
medline:
27
1
2021
Statut:
epublish
Résumé
The aim of the study was to develop a robust and standardized in vitro dissolution methodology for orally inhaled drug products (OIDPs). An aerosol dose collection (ADC) system was designed to uniformly deposit the whole impactor stage mass (ISM) over a large filter area for dissolution testing. All dissolution tests were performed under sink conditions in a sodium phosphate buffered saline solution containing 0.2%w/w sodium dodecyl sulphate. An adapted USP Apparatus V, Paddle over Disk (POD), was used throughout the study. The dissolution characteristics of the ISM dose of a commercial metered-dose inhaler (MDI) and a range of dry powder inhaler (DPI) formulations containing inhaled corticosteroids were tested. The uniform distribution of the validated ISM dose considerably reduced drug loading effects on the dissolution profiles for both MDI and DPI formulations. The improvement in the robustness and discriminatory capability of the technique enabled characterization of dissolution rate differences between inhaler platforms and between different DPI product strengths containing fluticasone propionate. A good correlation between in vivo mean absorption time and in vitro dissolution half-life was found for a range of the inhaled corticosteroids. The ADC system and the reproducible in vitro POD dissolution measurements provided a quantitative-based approach for measuring the relationship between the influence of device and the dispersion characteristics on the aerosol dissolution of low solubility compounds. The in vitro dissolution method could potentially be applied as a dissolution methodology for compendial, quality control release testing, and during development of both branded orally inhaled drug products and their generic counterparts.
Identifiants
pubmed: 32060670
doi: 10.1208/s12248-020-0422-y
pii: 10.1208/s12248-020-0422-y
pmc: PMC7021740
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Adrenergic beta-2 Receptor Agonists
0
Aerosols
0
Drug Combinations
0
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
47Références
PLoS One. 2013 Aug 14;8(8):e71339
pubmed: 23967195
J Pharm Pharmacol. 1986 Mar;38(3):161-5
pubmed: 2871148
Eur J Pharm Biopharm. 2009 May;72(1):156-64
pubmed: 19347972
Eur J Pharm Biopharm. 2007 Nov;67(3):732-42
pubmed: 17540551
Pharm Res. 2012 Aug;29(8):2157-66
pubmed: 22528980
J Aerosol Med Pulm Drug Deliv. 2010 Dec;23 Suppl 2:S71-87
pubmed: 21133802
Pharm Res. 1994 Nov;11(11):1557-61
pubmed: 7870671
AAPS PharmSciTech. 2012 Sep;13(3):978-89
pubmed: 22798037
Clin Pharmacol Ther. 2014 May;95(5):509-20
pubmed: 24503626
Eur J Pharm Sci. 2001 May;13(2):123-33
pubmed: 11297896
AAPS J. 2015 May;17(3):546-57
pubmed: 25758352
Br J Clin Pharmacol. 2001 Nov;52(5):529-38
pubmed: 11736861